A5091796151- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Hematopoietic Stem Cell Transplantation
- Cancer Genomics and Diagnostics
- Cancer therapeutics and mechanisms
- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Bone health and treatments
- Fungal Plant Pathogen Control
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Radiopharmaceutical Chemistry and Applications
- PI3K/AKT/mTOR signaling in cancer
- Acute Lymphoblastic Leukemia research
- Quinazolinone synthesis and applications
- HIV/AIDS drug development and treatment
- Lymphoma Diagnosis and Treatment
- Ubiquitin and proteasome pathways
- Blood groups and transfusion
- Hematological disorders and diagnostics
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Immunodeficiency and Autoimmune Disorders
Alfred Health
2015-2025
The Alfred Hospital
2015-2024
Monash University
2012-2023
Monash Medical Centre
2023
Australian Centre for HIV and Hepatitis Virology Research
2021-2022
Monash Alfred Psychiatry Research centre
2014-2021
The Royal Melbourne Hospital
2009-2013
Histone deacetylases (HDAC) control gene expression through their ability to acetylate proteins, thereby influencing a diverse range of cellular functions. Class I HDAC (HDAC1-3 and 8) HDAC6 are predominantly upregulated in malignancies altered some cancers has significant prognostic implication. The consequence dysregulated HDAC6, key players multiple myeloma (MM), unknown. This study hypothesized that MM patients with high have significantly poorer outcomes. Quantitative PCR for 11 (Class...
Multiple myeloma (MM) is a heterogeneous plasma cell disorder characterized by genetic abnormalities, including chromosomal translocations, deletions, duplications and mutations. Translocations involving the immunoglobulin heavy chain region at chromosome 14q32 are observed in approximately 40% of patients with MM. Translocation oncogenes into this may lead to their increased expression, contributing disease initiation, progression therapeutic resistance. The t(4;14) translocation associated...
Circulating free nucleic acids; cell DNA and circulating micro-RNA, are found in the plasma of patients with hematologic solid malignancies at levels higher than that healthy individuals. In malignancy reflects underlying tumor mutational profile, whilst micro-RNAs reflect genetic interference mechanisms within a potentially surrounding microenvironment immune effector cells. These acids offer simple, non-invasive, repeatable analysis can aid diagnosis, prognosis therapeutic decisions cancer...
Thirteen adult patients aged 22-63 (median 30) years with sickle cell disease (SCD) were enrolled in a regular erythrocytapheresis (ECP) programme at single institution between December 1998 and November 2008. The indications for enrolment recurrent painful crises (PC), acute chest syndrome (ACS), silent cortical ischaemia, pulmonary hypertension, multi-organ pregnancy. Endpoints retrospectively evaluated included the incidence of SCD-related events requiring hospitalization following prior...
Summary Central nervous system ( CNS ) multiple myeloma MM is exceedingly rare and portends a dismal prognosis. While immunomodulators have contributed to the improvement in survival , they appear limited activity against and, paradoxically, may contribute evolution of resistant clones capable surviving within . We undertook retrospective analysis characterize features outcome 17 patients from four institutions identified between 2000 2011. The median age was 58 years. Patients had received...
Multiple myeloma (MM) is a haematological malignancy characterised by the clonal proliferation of plasma cells in bone marrow. More than 80% patients with MM display evidence disease (MBD), formation osteolytic lesions throughout axial and appendicular skeleton. MBD significantly increases risk skeletal-related events such as pathologic fracture, spinal cord compression hypercalcaemia. result cells-mediated activation osteoclast activity suppression osteoblast activity. Bisphosphonates (BP),...
There is limited data describing dexamethasone, cyclophosphamide, etoposide, and cisplatin (DCEP) in relapsed refractory multiple myeloma (RRMM). We reviewed 65 patients with RRMM receiving DCEP between 2005 2017 two Melbourne Hospitals. Patients had received a mean of three prior treatment lines (range, 1-11). The number cycles was 1-4). Overall response rate (ORR) 55% whilst 19% achieved MR SD. Median overall survival (OS) 9.6 months. Those bridged to autologous stem cell transplant (ASCT)...
In preclinical studies, oral azacitidine (CC-486), a hypomethylating agent, has been shown to have direct anti-MM effect and in vitro synergism when combined with lenalidomide (LEN). We present phase 1b, single center, 3 × dose escalation study planned expansion at maximum tolerated (MTD), which assessed the safety efficacy of combining CC-486 LEN (25 mg d1-21/28) dexamethasone (DEX) (40 weekly) patients relapsed/refractory MM who had previously failed LEN. Twenty-four were enrolled. The MTD...
MEDI2228 is an antibody drug conjugate (ADC) comprised of a fully human B-cell maturation antigen (BCMA) conjugated to pyrrolobenzodiazepine (PBD) dimer. This phase 1 trial evaluated in patients with relapsed/refractory (R/R) multiple myeloma (MM), who received prior treatment approved agents from 3 classes antimyeloma drugs (proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies). Primary endpoint was safety tolerability; secondary endpoints included efficacy,...
Waldenström macroglobulinaemia ( WM ) is an indolent B‐cell malignancy characterised by the presence of immunoglobulin M IgM paraprotein and bone marrow infiltration clonal small B lymphocytes, plasmacytoid lymphocytes plasma cells. The symptoms are protean, often follow asymptomatic phase may include complications related to paraneoplastic effects paraprotein. revised 2016 World Health Organization classification includes MYD88 L265P mutation, which seen in >90% cases, within diagnostic...
Efficacy and safety of bortezomib-based consolidation following ASCT were investigated in newly diagnosed multiple myeloma patients from Australia, Korea, China. Patients received three cycles bortezomib-cyclophosphamide-dexamethasone induction followed by high-dose therapy/ASCT, then randomized (1:1) to with TP (thalidomide 100 mg/d for ≤12 months/until disease progression; prednisolone 50 mg on alternate days indefinitely/until n = 100) or VTP (subcutaneous bortezomib 1.3 mg/m2 every 2...
Measurable residual disease (MRD) is being recognised as an optimal method for assessing depth of response, identifying higher risk relapse, and guiding response-based treatment paradigms multiple myeloma (MM). Although MRD negativity increasingly replacing complete response the surrogate endpoint in clinical trials, its role real-world practice less established. We retrospectively analyzed EuroFlow results from patients with newly diagnosed MM (NDMM) who underwent bortezomib,...
LBH589 is a novel cinnamic hydroxamic acid analog (HAA) pan-histone deacetylase inhibitor (HDACi) currently in early phase clinical development.